Who is eligible for clinical trial NCT04022213?

Participants must meet protocol criteria for Desmoplastic Small Round Cell Tumor. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT04022213 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-20

A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum (NCT04022213)

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Memorial Sloan Kettering Cancer Center

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to test any good and bad effects of the study drug 131I-omburtamab. 131I-omburtamab could prevent the cancer from returning, or delay the cancer from getting worse, but it could also cause side effects. Researchers hope to learn more about how 131I-omburtamab works in the body, and how effective it is in treating cancer. 131I-Omburtamab is not approved by the FDA to treat DSRCT or other cancers of the peritoneum.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (7 items).

Location: Memorial Sloan Kettering Cancer Center — New York, New York

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Have the diagnosis of DSRCT confirmed at MSKCC
Age \>1 year and able to cooperate with radiation safety restrictions during therapy period.
Prior to intraperitoneal catheter placement
At least 1 weeks must have elapsed since prior chemotherapy
At least 2 weeks must have elapsed since biologic therapy
Toxicities of prior therapy must have resolved to grade 1 or less or to the patient's baseline At the completion of surgery, patients must fulfill all of the additional following criteria:
Have no definitive radiological evidence of disease active in liver or outside the abdomen/pelvic OR have had GTR of this disease at the time of catheter placement

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Prior progression of disease
Prior hypothermic intraperitoneal chemotherapy (HIPEC)
Cardiac, pulmonary, and neurologic toxicities are greater grade 1 per NCI CTCAE version 5
Renal, gastrointestinal, and hepatic, toxicities are greater than grade 2 (per NCI CTCAE version 5)
History of allergy to mouse proteins
Patients with grade 4 hypersensitivity reaction to radiolabeled iodine

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Memorial Sloan Kettering Cancer Center — New York, New York

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗